Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating the efficacy and safety of HBM9161 on moderate to severe thyroid eye disease (thyroid ophthalmopathy) in Phase 2 and Phase 3 is ongoing, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Ophthalmopathy

Drugs mentioned

• HBM9161

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Thyroid Ophthalmopathy | Phase 2, Phase 3 | Status: UNKNOWN